Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

The AMPLITUDE trial investigated the efficacy of adding niraparib, a PARP inhibitor, to abiraterone acetate and predniso...

Continue ReadingNiraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss

You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…

Continue ReadingGermline Testing: The Therapeutic Biomarker You Can’t Afford to Miss